115 related articles for article (PubMed ID: 19197721)
1. Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma.
Peinert S; Kamel S; Seymour JF; Prince HM
Leuk Lymphoma; 2009 Feb; 50(2):303-5. PubMed ID: 19197721
[No Abstract] [Full Text] [Related]
2. Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab.
Ferrer A; López-Guillermo A; Montoto S; Estrach T; Colomo L; Montserrat E
Ann Hematol; 2001 Aug; 80(8):479-81. PubMed ID: 11563595
[TBL] [Abstract][Full Text] [Related]
3. Rituximab chemotherapy regimens for treating advanced follicular lymphoma evaluated in new study.
Askeland G
Expert Rev Clin Immunol; 2013 May; 9(5):402. PubMed ID: 23772446
[No Abstract] [Full Text] [Related]
4. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
5. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation.
Wake B; Hyde C; Bryan S; Barton P; Song F; Fry-Smith A; Davenport C
Health Technol Assess; 2002; 6(3):1-85. PubMed ID: 12022936
[No Abstract] [Full Text] [Related]
6. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
7. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
[TBL] [Abstract][Full Text] [Related]
8. Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
Seiler T; Hiddemann W; Dreyling M
Immunotherapy; 2009 Nov; 1(6):1015-24. PubMed ID: 20635916
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival and orbital lymphoma.
Shinder R
Ophthalmology; 2011 Aug; 118(8):1692; author reply 1692, 1692.e1. PubMed ID: 21813098
[No Abstract] [Full Text] [Related]
10. Meningeal relapse by follicular lymphoma as a single mass.
Moreno García V; Redondo A; Fernández Zubillaga A; González-Barón M
Clin Transl Oncol; 2008 Mar; 10(3):180-1. PubMed ID: 18321822
[TBL] [Abstract][Full Text] [Related]
11. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
13. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.
Hirt C; Schüler F; Dölken G
Semin Cancer Biol; 2003 Jun; 13(3):223-31. PubMed ID: 12959353
[TBL] [Abstract][Full Text] [Related]
16. Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab.
Scaramucci L; Perrotti A; Niscola P; Fratoni S; Palombi M; Piccioni D; Cupelli L; Tendas A; Dentamaro T; Del Poeta G; De Fabritiis P
Leuk Lymphoma; 2007 Sep; 48(9):1878-80. PubMed ID: 17786731
[No Abstract] [Full Text] [Related]
17. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.
Lazzarino M; Arcaini L; Orlandi E; Iacona I; Bernasconi P; Calatroni S; Varettoni M; Isa L; Brusamolino E; Bonfichi M; Passamonti F; Burcheri S; Pascutto C; Regazzi M
Oncology; 2005; 68(2-3):146-53. PubMed ID: 16006752
[TBL] [Abstract][Full Text] [Related]
18. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
Cicone F; Russo E; Carpaneto A; Prior JO; Delaloye AB; Scopinaro F; Ketterer N
Hematol Oncol; 2011 Sep; 29(3):131-8. PubMed ID: 20862654
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F; Radford J; Van Hoof A; Vitolo U; Soubeyran P; Tilly H; Huijgens PC; Kolstad A; d'Amore F; Gonzalez Diaz M; Petrini M; Sebban C; Zinzani PL; van Oers MH; van Putten W; Bischof-Delaloye A; Rohatiner A; Salles G; Kuhlmann J; Hagenbeek A
J Clin Oncol; 2008 Nov; 26(32):5156-64. PubMed ID: 18854568
[TBL] [Abstract][Full Text] [Related]
20. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects.
Maloney DG
Hematology Am Soc Hematol Educ Program; 2007; ():226-32. PubMed ID: 18024634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
